Edition:
United Kingdom

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

1.95USD
18 Jul 2018
Change (% chg)

$-0.21 (-9.72%)
Prev Close
$2.16
Open
$2.25
Day's High
$2.27
Day's Low
$1.86
Volume
1,651,760
Avg. Vol
423,803
52-wk High
$4.24
52-wk Low
$1.86

Chart for

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $454.30
Shares Outstanding(Mil.): 118.31
Dividend: --
Yield (%): --

Financials

  AVEO.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -0.56 -- --
ROI: -166.61 2.21 14.61
ROE: -- 3.85 16.34

BRIEF-Aveo Reports Q1 Loss Per Share $0.08

* AVEO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

08 May 2018

BRIEF-Aveo Quarterly Loss Per Share $0.08

* AVEO REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

13 Mar 2018

BRIEF-Aveo Pharmaceuticals ‍Entered Into Sales Agreement With Leerink Partners

* AVEO PHARMACEUTICALS SAYS ‍ENTERED INTO A SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING

16 Feb 2018

BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda

* AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA

12 Feb 2018

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥4,662 -45.00
Eisai Co., Ltd (4523.T) ¥11,200 +235.00
Pfizer Inc. (PFE.N) $37.66 +0.01
Novartis AG (NOVN.S) CHF80.66 +2.46
Roche Holding Ltd. (ROG.S) CHF234.75 +2.75
Roche Holding Ltd. (RO.S) CHF238.80 +2.00
Bayer AG (BAYGn.DE) €92.96 -0.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €72.51 --
AstraZeneca plc (AZN.L) 5,606.00 +55.00

Earnings vs. Estimates